We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Shannon Westin

Shannon N. Westin MD, MPH

Associate Professor, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas

Recent Contributions to PracticeUpdate:

  1. PARP Inhibitors in Advanced Ovarian Cancer
  2. Olaparib Maintenance Retreatment in Epithelial Ovarian Cancer
  3. Pembrolizumab With Chemotherapy as First Line for Metastatic Cervical Cancer
  4. Olaparib With or Without Cediranib vs Standard of Care for Recurrent Platinum-Sensitive Ovarian Cancer
  5. Barriers to Use of PARP Inhibitor Maintenance for Patients With Ovarian Cancer
  6. Addition of Immunotherapy and PARP Inhibition to Carboplatin Plus Paclitaxel for Advanced Endometrial Cancer
  7. Microsatellite Instability and Endometrial Cancer
  8. Key Gynecologic Oncology Presentations at ESMO 2019
  9. Niraparib Maintenance and Thrombocytopenia for Recurrent Ovarian Cancer
  10. ESMO: Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

Most Read This Week

Recently Updated